Results 261 to 270 of about 367,294 (339)

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz, Aidan Shulkin, Asmaa Housni, Amélie Roy‐Fleming, Rémi Rabasa‐Lhoret, Jean‐Francois Yale, Michael A. Tsoukas, Tricia M. Peters, Anne‐Sophie Brazeau   +8 more
wiley   +1 more source

Retrospective analysis of the diagnostic spectrum of histological nephropathies from the Magdeburg kidney biopsy cohort (MD-KBC). [PDF]

BMC Nephrol
Mertens PR, Kanaan MR, Abou-Watfa AA, Bender ST, Wiech T, Gröne HJ, Scurt FG.   +6 more
europepmc   +1 more source

Correction to "Calorie Restriction Protects against Contrast-Induced Nephropathy via SIRT1/GPX4 Activation". [PDF]

Oxid Med Cell Longev
europepmc   +1 more source

Diabetes mellitus with anti-glomerular basement membrane disease and anti-tubular basement membrane disease: a rare case report of reversible dialysis dependence. [PDF]

Front Immunol
Hu J, Liang Y, Sun K, Xiao Y.
europepmc   +1 more source

Association between daily steps, diabetes management and health indicators in people living with type 1 diabetes: A cross‐sectional study from the BETTER registry

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims In people with type 1 diabetes, physical activity provides important health benefits but is mainly limited by fear of hypoglycaemia. Daily step count is a simple indicator of ambulatory activity. This study examined associations between step count and health indicators.
Thélo I. Garré, Capucine G. Guédet, Laure Alexandre‐Heymann, Virginie Messier, Valérie Boudreau, Semah Tagougui, Claude Laforest, Anne‐Sophie Brazeau, Rémi Rabasa‐Lhoret, Jane E. Yardley   +9 more
wiley   +1 more source

Integrated bioinformatics and machine learning reveal pan-apoptosis and immune infiltration signatures in diabetic nephropathy. [PDF]

Front Immunol
Liu Y, Lu W, Xiang Z, Shen Y, Ni B, Zou H, Shao X.   +6 more
europepmc   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source

Efficacy of Low-Dose Intravenous Immunoglobulin Combined With Immunosuppression Modification in the Treatment of BK Polyomavirus Nephropathy: A Case Series. [PDF]

Cureus
Eswarappa M, George J, Kc G, R R, M S G, Prabhu PP, Reddy H, Yousuff M, Veluru R.   +8 more
europepmc   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source